Journal of Pediatric Epilepsy 2020; 9(03): 073-079
DOI: 10.1055/s-0040-1712147
Review Article

Ethical Issues in Pediatric Regulatory Studies Involving Placebo Treatment

Klaus Rose
1  Klausrose Consulting, Riehen, Switzerland
,
David Neubauer
2  Department of Child, Adolescent and Developmental Neurology, University Childrens' Hospital, Ljubljana, Slovenia
,
Jane M. Grant-Kels
3  Department of Dermatology, UConn Health, Farmington, Connecticut, United States
› Author Affiliations

Abstract

Separate pediatric studies for antiepileptic drugs (AEDs) emerged with general separate drug approval in children and were defined by the U.S. Food and Drug Administration (FDA) as <17 years and by the European Union (EU) as <18 years. These administrative age limits are necessary in pediatrics, but they correspond variably with the physiological maturity of young patients and are not helpful for therapeutic decisions or as study inclusion criteria. AEDs are often effective for partial onset seizures (POS) in 2 to 17-year-olds as well as in ≥18-year-olds, if dosed correctly. Separate pediatric AED studies assume no difference between the legal and the physiological meaning of the word “child.” While the FDA now accepts efficacy of AEDs in POS in children ≥2 years, the EU still requires separate “pediatric” studies. For retigabine it waived all pediatric studies after having required 20 such studies over several years. We feel the current regulation creates a situation where many studies in children are done unnecessarily; we question the ethics of such an approach, which in our view, is morally wrong. Critical publications contributed to the FDA's shift of opinion for AEDs in POS but did not address the blur of different meanings of the word “child.”



Publication History

Received: 27 February 2020

Accepted: 31 March 2020

Publication Date:
04 June 2020 (online)

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Stuttgart · New York